Coherus Oncology, Inc. (CHRS)

Market Cap	140.21M
Revenue (ttm)	277.73M
Net Income (ttm)	154.97M
Shares Out	120.87M
EPS (ttm)	1.34
PE Ratio	2.20
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	622,800
Open	1.200
Previous Close	1.210
Day's Range	1.160 - 1.230
52-Week Range	0.710 - 2.430
Beta	0.94
Analysts	Strong Buy
Price Target	4.51 (+288.79%)
Earnings Date	Nov 6, 2025

About CHRS

Coherus Oncology, Inc., a biopharmaceutical company, researches, develops, and commercializes immunotherapies to treat cancer in the United States. The company develops UDENYCA, a biosimilar to Neulasta, a long-acting granulocyte-colony stimulating factor; LOQTORZI, a novel next-generation programmed death receptor-1 inhibitor; and Casdozokitug, an investigational recombinant human immunoglobulin isotype (IgG1) monoclonal antibody targeting interleukin 27. It also develops CHS-114, an investigational highly specific human afucosylated IgG1 mono...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 6, 2014
• Employees: 228
• Stock Exchange: NASDAQ
• Ticker Symbol: CHRS
• Website: https://www.coherus.com

Analyst Summary

According to 4 analysts, the average rating for CHRS stock is "Strong Buy." The 12-month stock price target is $4.51, which is an increase of 288.79% from the latest price.

Price Target

$4.51

(288.79% upside)

Analyst Consensus: Strong Buy